Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – Leerink Swann cut their FY2018 earnings per share (EPS) estimates for shares of Achillion Pharmaceuticals in a report issued on Monday. Leerink Swann analyst J. Schwartz now expects that the biopharmaceutical company will post earnings of ($0.79) per share for the year, down from their previous estimate of ($0.29). Leerink Swann has a “Outperform” rating and a $6.00 price target on the stock.
Several other equities analysts have also issued reports on the company. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. Ladenburg Thalmann Financial Services dropped their price target on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a research note on Tuesday. Robert W. Baird reissued a “neutral” rating and issued a $4.00 price target (down from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday. ValuEngine lowered Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday. Finally, BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 16th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $7.69.
Shares of Achillion Pharmaceuticals (ACHN) traded up 3.782% during mid-day trading on Wednesday, reaching $3.705. 1,369,104 shares of the company’s stock traded hands. The company has a 50 day moving average of $4.52 and a 200 day moving average of $4.20. The company’s market cap is $506.70 million. Achillion Pharmaceuticals has a 12 month low of $3.15 and a 12 month high of $9.19.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). During the same quarter last year, the company earned ($0.14) EPS.
Several large investors have recently modified their holdings of ACHN. Cambridge Investment Research Advisors Inc. raised its position in shares of Achillion Pharmaceuticals by 3.6% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 800 shares during the period. SG Americas Securities LLC raised its position in shares of Achillion Pharmaceuticals by 18.6% during the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 4,144 shares during the period. Teza Capital Management LLC acquired a new position in shares of Achillion Pharmaceuticals during the first quarter worth approximately $131,000. TradeLink Capital LLC acquired a new position in shares of Achillion Pharmaceuticals during the second quarter worth approximately $132,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Achillion Pharmaceuticals during the first quarter worth approximately $138,000. 74.12% of the stock is currently owned by institutional investors.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.